Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy.

A H Schönthal

Journal: British journal of cancer 2008;97(11):1465-8

PMID: 17955049

Free Full Text on PubMed Central View on PubMed

Abstract

Celecoxib (Celebrex) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain. However, it now appears that this compound harbours additional pharmacologic activities that are entirely independent of its COX-2-inhibitory activity. This review presents the recently emerged direct non-COX-2 targets of celecoxib and their proposed role in mediating this drug's antitumour effects.

Address: Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. [email protected]

DOI: 10.1038/sj.bjc.6604049